Esomeprazole (Dispep, Trusfluks)
Esomeprazole
Innovata pharmaceuticals
Registration
- Applicant
- Innovata pharmaceuticals
- Registrations
- 4
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Dispep 20 Each gastro-resistant tablet contains ESOMEPRAZOLE MAGNESIUM DIHYDRATE EQUIVALENT TO ESOMEPRAZOLE 20,0 mg | 20 | 48093448/11.4.3/0934 | Registered | Not determined | None |
| Dispep 40 Each gastro-resistant tablet contains ESOMEPRAZOLE MAGNESIUM DIHYDRATE EQUIVALENT TO ESOMEPRAZOLE 40,0 mg | 40 | 48093548/11.4.3/0935 | Registered | Not determined | None |
| Trusfluks 20 EACH TABLET CONTAINS ESOMEPRAZOLE 20,0 mg | 20 | 59032559/11.4.3/0325 | Registered | Not determined | None |
| Trusfluks 40 EACH TABLET CONTAINS ESOMEPRAZOLE 40,0 mg | 40 | 59032659/11.4.3/0326 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Esomeprazole
- except when indicated for the temporary, short-term relief of heartburn and hyperacidity, subject to:
- a maximum daily dose of 20 milligrams
- a maximum treatment period of 14 days. (S2)
Consolidated Schedules 06 July 2026, lines 6239 to 6244
S2: Esomeprazole
- when indicated for the temporary, short-term relief of heartburn and hyperacidity subject to:
- a maximum daily dose of 20 milligrams
- a maximum treatment period of 14 days. (S4)
Consolidated Schedules 06 July 2026, lines 1921 to 1925
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
6-Methoxy-2-[(S)-(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole
Drag to rotate. Structure from PubChem CID 9568614.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.